Skip to main content
TLSI logo

TLSI · TriSalus Life Sciences, Inc. · Metrics

Track TLSI — free
$4.76 +0.03 (+0.63%) At close · Sep 9
Market Cap
$307.87M
Shares
61.57M

TLSI metrics

66 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.73
Market cap
$307.87M

Price action

20 metrics
Price change (1W)
-8.5%
Price change (30D)
-15.2%
Price change (3M)
+41.6%
Price change (6M)
+11.0%
Price change (YTD)
-32.2%
Price change (1Y)
-5.6%
Trailing year
Price change (5Y)
-52.2%
52-week high
$7.50
52-week low
$2.52
Change from 52-week high
-36.9%
Change from 52-week low
+87.7%
Annualized volatility
79.3%
Annualized volatility (3M)
70.9%
Beta
1.2
RSI (14D)
42.9
Price vs SMA 50
-0.2%
Price vs SMA 200
-2.2%
Avg volume (3M)
291,077
Relative volume
0.4
Average dollar volume
$1.31M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
61.57M

Valuation

12 metrics
P / E (TTM)
Trailing earnings
PEG ratio
EV / revenue
6.5×
reciprocal yield 15.3%
EV / EBITDA
EV / EBIT
P / sales
6.8×
reciprocal yield 14.6%
P / book
47.0
reciprocal yield 2.1%
FCF yield
TTM · current market cap
Buyback yield
P / FCF
P / operating cash flow
Earnings yield
-9.2%

Historical valuation

8 metrics
P / E historical average (3Y)
P / E historical average (5Y)
EV / revenue historical average (3Y)
EV / revenue historical average (5Y)
EV / EBIT historical average (3Y)
EV / EBIT historical average (5Y)
EV / EBITDA historical average (3Y)
EV / EBITDA historical average (5Y)

Dividends & buybacks

7 metrics
Dividend yield
Trailing 12 months
Payout ratio
Shareholder yield
Dividend / share (TTM)
Dividend growth YoY
Dividend growth streak
Last ex-dividend

Earnings calendar

2 metrics
Next earnings
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
85.8%
Operating margin
-67.7%
Trailing 12 months
Net margin
-62.6%
Gross profit (TTM)
$38.67M
Operating profit (TTM)
−$30.51M
Net income (TTM)
−$28.21M
Trailing 12 months
Diluted EPS (TTM)
$-1.31
FCF margin
Effective tax rate

Per share

11 metrics
Revenue per diluted share (TTM)
Gross profit per diluted share (TTM)
Operating profit per diluted share (TTM)
EBITDA per diluted share (TTM)
Net income per diluted share (TTM)
Operating cash flow per diluted share (TTM)
Free cash flow per diluted share (TTM)
Capital expenditures per diluted share (TTM)
R&D per diluted share (TTM)
Stock compensation per diluted share (TTM)
Book value per share
$-0.68

Growth

11 metrics
Revenue growth YoY
+1.7%
Year over year
Net income growth YoY
Revenue (TTM)
$45.08M
Trailing 12 months
EPS growth YoY
Shares change YoY
+77.2%
Year over year · more shares
Revenue CAGR (3Y)
+53.9%
Revenue CAGR (5Y)
EPS CAGR (3Y)
EPS CAGR (5Y)
FCF CAGR (3Y)
FCF CAGR (5Y)

Quality

14 metrics
Return on equity
-430.7%
Return on assets
-45.2%
Debt / equity
5.0
Current ratio
5.3
EBITDA (TTM)
−$29.95M
Free cash flow (TTM)
Quick ratio
5.0
Interest coverage
-5.2
Net debt / EBITDA
Return on invested capital
Trailing 12 months
Net cash
$13.22M
Latest balance sheet
Cash & equivalents
$46.29M
Total assets
$62.45M
Total debt
$33.06M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$22.80M
Capital expenditures (TTM)
$480,000
R&D (TTM)
$14.63M
SG&A (TTM)
Stock compensation (TTM)
$10.71M
R&D / revenue
32.4%
Stock compensation / revenue
23.8%

Ownership (13F)

3 metrics
13F filers
83
13F filer change QoQ
-8
Institutional ownership
37.0%

Short interest

3 metrics
Short interest
6.2%
Latest settlement · 14.0 days to cover
Days to cover
14.0d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
Insider-sentiment score

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1826667 CUSIP 89680M101 13F (30d) 47 filings 47 filers Visit website Investor relations